Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EBT (2016 - 2025)

Dare Bioscience (DARE) has disclosed EBT for 8 consecutive years, with -$3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 21.56% year-over-year to -$3.7 million, compared with a TTM value of -$17.4 million through Sep 2025, up 25.3%, and an annual FY2024 reading of -$23.5 million, up 24.2% over the prior year.
  • EBT was -$3.7 million for Q3 2025 at Dare Bioscience, up from -$3.8 million in the prior quarter.
  • Across five years, EBT topped out at $384322.0 in Q2 2022 and bottomed at -$16.2 million in Q4 2022.
  • Average EBT over 5 years is -$7.2 million, with a median of -$7.4 million recorded in 2024.
  • The sharpest move saw EBT soared 104.19% in 2022, then crashed 2439.02% in 2023.
  • Year by year, EBT stood at -$9.5 million in 2021, then plummeted by 70.08% to -$16.2 million in 2022, then surged by 68.14% to -$5.2 million in 2023, then decreased by 4.19% to -$5.4 million in 2024, then soared by 31.85% to -$3.7 million in 2025.
  • Business Quant data shows EBT for DARE at -$3.7 million in Q3 2025, -$3.8 million in Q2 2025, and -$4.6 million in Q1 2025.